Feiyang Liu
High Magnetic Field Laboratory
Hefei, China
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Fluoroacetate-Mediated Dual-Interface Ionic Stabilization in Perovskite Solar Cells.
Journal: Advanced materials (Deerfield Beach, Fla.)
Published: January 22, 2026
Unified Interface-Bulk Enhancements in Wide-Bandgap Perovskites Enabled by Bifunctional Cyanoacetic Acid for Textured Silicon/Perovskite Tandem Solar Cells.
Journal: Advanced materials (Deerfield Beach, Fla.)
Published: December 14, 2025
Effect of Tongdu Tiaoshen acupuncture on neuroinflammation in rats with CUMS based on the miR-26a-5p/EZH2/H3K27me3 pathway
Journal: Zhongguo zhen jiu = Chinese acupuncture & moxibustion
Published: June 29, 2025
Discovery of dihydropyridinone derivative as a covalent EZH2 degrader.
Journal: European journal of medicinal chemistry
Published: July 26, 2023
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.
Journal: Signal transduction and targeted therapy
Published: May 07, 2022
Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours.
Journal: Molecular oncology
Published: July 06, 2021
Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences.
Journal: Molecular biomedicine
Published: January 01, 2020
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.
Journal: Experimental cell research
Published: November 19, 2019
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.
Journal: Journal of medicinal chemistry
Published: June 29, 2019
Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.
Journal: Therapeutic advances in medical oncology
Published: October 06, 2018
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.
Journal: Cancer letters
Published: September 30, 2018
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Journal: European journal of medicinal chemistry
Published: March 30, 2018
Last Updated: 09/26/2026